Drug intelligence / Profile preview

RO7497372

Development stage: Phase 1
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

RO7497372 is an investigational drug developed by Genentech for the treatment of diabetic macular edema (DME). It is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) are being evaluated following intravitreal administration in adults with DME. The study involves multiple ascending doses to assess ocular and systemic effects. The precise mechanism of action has not been publicly disclosed as of April 2025; however, based on its development context and trial design, it is likely a biologic agent intended for retinal vascular diseases.

Beyond the preview

Go deeper on RO7497372.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7497372.

Explore the full profile